Xilio Therapeutics Reports Improved Q1 Financials, Extends Cash Runway, and Announces CMO Resignation

summarizeSummary

Xilio Therapeutics announced improved Q1 financials with a reduced net loss and increased revenue, extending its cash runway into early 2028. The company also reported the resignation of its Chief Medical Officer.

check_boxKey Events

• Improved Q1 Financial Performance

  Net loss for Q1 2026 decreased to $9.5 million from $13.3 million in Q1 2025, driven by a substantial increase in collaboration and license revenue to $12.6 million from $2.9 million.

• Extended Cash Runway

  The company's cash and cash equivalents of $150.3 million as of March 31, 2026, combined with a $6.0 million milestone payment in Q2 2026, are expected to fund operations into early 2028.

• Chief Medical Officer Resignation

  Dr. Katarina Luptakova resigned as Chief Medical Officer, effective May 31, 2026. Dr. Martin Huber, a former Xilio executive, was appointed as an interim medical and clinical consultant.

• Principal Accounting Officer Appointment

  Christopher Frankenfield, the current Chief Financial Officer and Chief Operating Officer, was also appointed as the Principal Accounting Officer.

auto_awesomeAnalysis

Xilio Therapeutics reported a reduced net loss of $9.5 million for Q1 2026, an improvement from $13.3 million in Q1 2025. Collaboration and license revenue significantly increased to $12.6 million from $2.9 million year-over-year. The company's cash and cash equivalents stood at $150.3 million as of March 31, 2026, and, including a $6.0 million milestone achieved in Q2 2026, are projected to fund operations into early 2028. This extends their cash runway, a critical positive for a clinical-stage biotechnology company. Concurrently, Dr. Katarina Luptakova resigned as Chief Medical Officer, effective May 31, 2026, with Dr. Martin Huber appointed as an interim medical and clinical consultant. Christopher Frankenfield, the CFO and COO, also assumed the role of Principal Accounting Officer.